Journal: Biochemical Journal
Article Title: Unconventional binding of calmodulin to CHK2 kinase inhibits catalytic activity
doi: 10.1042/BCJ20253431
Figure Lengend Snippet: (A ) Schematic of the conventional mode of Ca 2+ -CaM activation in members of the Ca 2+ -CaM-dependent protein kinase (CaMK) family. Upon Ca 2+ influx, Ca 2+ -CaM binds a linear sequence (CaM-binding sequence; CaMBS; orange) that is proximal to the CaMK kinase domain (blue). This interaction restores activity by sequestering an autoinhibitory pseudosubstrate sequence, which formerly obstructed the active site. ( B ) Far Western blots show that recombinant full-length CHK2 and positive control kinase, CaMKK2, interact with His 6 -CaM in a Ca 2+ -dependent manner (Ca 2+ : 500 μM), as binding is abolished in the presence of the Ca 2+ -chelator, EGTA (10 mM). A negative control pseudokinase, MLKL, did not detectably bind CaM. CaM interaction was detected using an anti-His 6 HRP antibody. data are representative of two independent replicates. ( C ) CHK2 is inhibited by Ca 2+ -CaM. Full-length wildtype and K249A kinase-dead CHK2 were immunoprecipitated and activity was measured by radiometric assay containing 200 μM CHKtide, 200 μM [ 32 P]-γ-ATP and in the presence (red) or absence (white) of 200 μM CaCl 2 , 1 mM CaM for 10 min. Two-way ANOVA; **** P <0.0001; n.s = non-significant. ( D ) Double referenced SPR sensorgrams for immobilised full-length CHK2 binding to analyte, Ca 2+ -CaM. Shown is a representative sensorgram that is colour-coded based on CaM concentration. ( E ) Steady state analysis for the SPR experiment shown in ( D ), along with the dissociation constant. ( F ) Titration of CaM (range 0, 0.5, 1, 2, 5, 10, 20, 50, 100, 200 μM) using immunoprecipitated full-length CHK2 (~10 ng) in the presence of 1 mM CaCl 2 by radiometric assay. The half-maximal inhibitory concentration (IC 50 ) for CaM is 8.1 μM. Data represent mean ± SD; n = 3. ( G ) Plot of highest and lowest CHK2 kinase activity from CaM titration the presence of 1 mM CaCl 2 . Individual data points are shown as circles with accompanying mean ± SD; n = 3. Statistical analysis was performed by unpaired t-test; **** P <0.0001. ( H ) Titration of CaCl 2 (range 0, 1, 2, 5, 10, 20, 50, 100, 200, 500, 1000 μM) using immunoprecipitated full-length CHK2 (~10 ng) in the presence of 200 μM CaM by radiometric assay. the IC 50 of CHK2 and CaM by Ca 2+ is 30.7 μM. Data represent mean ± SD; n = 3. ( I ) Plot of highest and lowest CHK2 kinase activity from CaCl 2 titration in the presence of 200 μM CaM. individual data points are shown as circles with accompanying mean ± SD; n = 3. Statistical analysis was performed by unpaired t-test; *** P <0.001. ( J ) Schematic of the amino acid residues of recombinant full-length CHK2 and CaM (red) chemically cross-linked by DMTMM (‘zero-length’) and ( K ) photoactivatable cross-linker, NHS-Diazarine (SDA; 3.9 Å spacer), following mass-spectrometry analysis. Cross-links (grey) are only observed within the CHK2 kinase domain (blue) for both chemical cross-linkers. ( L ) Six lysine residues in CHK2, identified by DMTMM chemical cross-linking are mapped to the domain architecture of CHK2. ( M ) Radiometric assay of immunoprecipitated CHK2 wildtype and select cross-linked lysine mutants in the presence (red) or absence (white) of 200 μM CaCl 2 , 1 mM CaM for 10 min. Note: wildtype and K249A kinase-dead data are reproduced from ( C ). Data represent mean ± SD; n = 3. Statistical analysis was performed by two-way ANOVA; * and **** P <0.1 and P <0.0001, respectively; n.s = non-significant. Assay data using recombinant CHK2 kinase domain with each cross-linked lysine mutant are shown in .
Article Snippet: Primary antibodies used in this study for immunoblotting were: rabbit anti-His 6 -HRP-conjugated (Abcam; clone ab1187: 1:5000); rat anti-FLAG (WEHI clone 9H1; produced in-house; 1:1000); rabbit anti-phospho-Thr383 CHK2 (ThermoFisher; catalog PA5-104714; 1:1000); mouse anti-CHK2 (Cell Signaling Technology; clone 1C12; 1:1000); mouse anti-actin, (Sigma-Aldrich, A-1978; 1:1000).
Techniques: Activation Assay, Sequencing, Binding Assay, Activity Assay, Western Blot, Recombinant, Positive Control, Negative Control, Immunoprecipitation, Concentration Assay, Titration, Mass Spectrometry, Mutagenesis